Purchase of technology-powered CRO grows Aixial's offerings in clinical operations and product development
France-based Aixial, the CRO of Alten Group, has acquired UK portfolio company Cmed Group by Alten Europe, an engineering and technology consultant. Cmed is a technology-led CRO that specializes in full-service oncology, immuno-oncology, cell therapy and rare diseases, and the delivery of data and analytic services. Cmed also has a tech division that developed Encapsia, a clinical data suite purpose created to support traditional, decentral, virtual and hybrid clinical trials.
Cmed has provided biopharma and medical device partners across the globe with clinical operations, data sciences and analytics, regulatory affairs, pharmacovigilance and product development services, for more than two decades.
By partnering with Aixial, the combined group now has widespread geographical coverage, with the capability to support customers with a wide range of expertise and solutions. Clients will benefit, executives say, from the ability to quickly and dependably scale, while Encapsia will be enhanced to allow customers to have services and technology improved to deliver various types of clinical trials.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In
October 30th 2024In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.